SU5416 delays wound healing through inhibition of TGF-β1 activation

Zishan A. Haroon, Khalid Amin, Wilfred Saito, William Wilson, Charles S. Greenberg, Mark W. Dewhirst

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


Angiogenesis, development of new blood vessels, is essential for wound healing and tumor growth. A potentially important side effect of anti-angiogenic therapy can be delayed wound healing. In this study we address this issue by using a novel in vivo method utilizing fibrin containing dual porous plexiglass chambers (Fibrin Z-Chambers; F-ZC) to investigate wound healing in rats administered with SU5416 (inhibitor of Flk-1 and Flt-1, at 20 mg/kg IP). SU5416 treated F-ZCs developed 45% less granulation tissue (p=0.0076) and showed a 10% reduction in microvessel density (p=0.0009) than controls treated with drug carrier alone. The granulation tissue showed distinctly decreased collagen deposition (p=0.0006) in SU5416 treated animals that was associated with 90% reduction in active TGF-β1 level. We found that tissue transglutaminase (TG), a cross-linking enzyme involved in TGF-β1 activation and matrix stabilization, was inhibited by SU5416. These results suggest that SU5416 delays wound healing by reducing matrix synthesis and stabilization through inhibition of TGF-β1 activation. This study was made feasible via the development of a unique method to study anti-angiogenic compounds that provides highly reproducible and quantitative results. Further studies are needed to evaluate in vivo whether anti-angiogenic agents alter wound healing.

Original languageEnglish (US)
Pages (from-to)121-126
Number of pages6
JournalCancer Biology and Therapy
Issue number2
StatePublished - 2002


  • Anti-angiogenesis
  • Fibrin
  • SUGEN 5416
  • Tissue transglutaminase
  • Z-chambers


Dive into the research topics of 'SU5416 delays wound healing through inhibition of TGF-β1 activation'. Together they form a unique fingerprint.

Cite this